Search company, investor...
Tissue Genesis company logo

Tissue Genesis


Unattributed - II | Alive

Total Raised


Last Raised

$500K | 9 yrs ago

About Tissue Genesis

Tissue Genesis develops advanced tissue engineering and cell therapy solutions, using adipose (fat) derived regenerative medicine solutions to address a range of medical needs.

Headquarters Location

810 Richards Street Suite 1000

Honolulu, Hawaii, 96813,

United States


Missing: Tissue Genesis's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Tissue Genesis's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Tissue Genesis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tissue Genesis is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Tissue Genesis Patents

Tissue Genesis has filed 14 patents.

The 3 most popular patent topics include:

  • Biomaterials
  • Cell biology
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Clusters of differentiation, Cell biology, Biomaterials, Biotechnology


Application Date


Grant Date



Related Topics

Transcription factors, Clusters of differentiation, Cell biology, Biomaterials, Biotechnology



Latest Tissue Genesis News

FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2(R) to Treat ARDS Resulting from COVID-19 Infection

May 7, 2021

Search jobs 07-May-2021 FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2(R) to Treat ARDS Resulting from COVID-19 Infection FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2(R) to Treat ARDS Resulting from COVID-19 Infection     Germantown, Md., US, May 7, 2021 -  Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, announces it has been granted Investigational Device Exemption (IDE) approval by the United States Food and Drug Administration (FDA) to conduct a first-in-human feasibility study of the Tissue Genesis Icellator2(R) to treat Acute Respiratory Distress Syndrome (ARDS) resulting from COVID-19 infection. The Tissue Genesis Icellator2 is a point-of-care cell isolation device that rapidly recovers high yields of stromal and vascular cells (“SVF”) from adipose tissue (fat) to be used therapeutically. The SVF derived from the Icellator2 contains a population of mesenchymal stem cells, vascular endothelial cells, and immune cells which migrate to the patient’s lungs and other peripheral sites of inflammation. Published nonclinical and clinical evidence indicate that SVF from the Icellator2 may potentially: (1) stabilize microcirculation to improve oxygenation; (2) maintain T and B lymphocytes to support antibody production; and (3) induce an anti-inflammatory effect. Orgenesis believes the multiple mechanisms of action of the SVF derived from the Icellator2 are important to treat ARDS and other inflammatory disorders. The FDA IDE approval covers 21 patients at one clinical site in the United States. This is the first trial approved by the FDA for intravenous administration of the SVF produced by the Icellator2. The rates of hospitalized patients in the U.S. suffering from ARDS resulting from COVID-19 has declined significantly in recent months. Orgenesis will monitor and evaluate current clinical needs prior to initiating this approved pilot trial. Orgenesis may consider amending its clinical development plan to target treatment of non-COVID-19 related ARDS or treatment of patients who have not recovered from prior COVID-19 infections (so called “long haulers”). Matthew Lehman, U.S. POCare General Manager, stated, “We believe that the FDA’s IDE authorization of the Tissue Genesis Icellator2 clinical trial is a significant milestone for the Company. We are excited to move forward with clinical development of the Icellator to treat ARDS, COVID-19-related complications, and other serious conditions. Our interactions with the FDA through the IDE process will inform our development plans. We look forward to providing further updates on the progress of our Icellator2 clinical trial.”   About Orgenesis Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. Learn more about the work Orgenesis is doing at . Notice Regarding Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our point-of-care cell therapy platform, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs that are based on novel technologies, our ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, our ability to manage potential disruptions as a result of the coronavirus outbreak, the sufficiency of working capital to realize our business plans, the development of our POCare strategy, our trans differentiation technology as therapeutic treatment for diabetes, the technology behind our in-licensed ATMPs not functioning as expected, our ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfill our obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason. Editor Details

Tissue Genesis Frequently Asked Questions (FAQ)

  • Where is Tissue Genesis's headquarters?

    Tissue Genesis's headquarters is located at 810 Richards Street , Honolulu.

  • What is Tissue Genesis's latest funding round?

    Tissue Genesis's latest funding round is Unattributed - II.

  • How much did Tissue Genesis raise?

    Tissue Genesis raised a total of $37.27M.

  • Who are the investors of Tissue Genesis?

    Investors of Tissue Genesis include Hawaii Angels, BioStar and TGI Investment.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.